Jefferies Downgrades Edwards Lifesciences to Hold, Lowers Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Matthew Taylor has downgraded Edwards Lifesciences from Buy to Hold and reduced the price target from $85 to $70.
September 18, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Jefferies has downgraded Edwards Lifesciences from Buy to Hold, with a reduced price target of $70, indicating a less optimistic outlook.
The downgrade from Buy to Hold by Jefferies, along with a lowered price target, suggests a less favorable view on Edwards Lifesciences' near-term performance. This is likely to exert downward pressure on the stock price as investors adjust their expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100